RACHEL FRY: Open Payments
NPI 1477219137 · YUMA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$491 in 20 payments from 10 companies in 2025. Trend: 2023 $271 · 2024 $1,728 · 2025 $491
Food & beverage: $491
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 3 | $102 |
| GENZYME CORPORATION | 3 | $75 |
| GlaxoSmithKline, LLC. | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| HARMONY BIOSCIENCES LLC | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Amgen Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| United Therapeutics Corporation | 1 | $25 |
| Verona Pharma, Inc. | 1 | $20 |
Products named: DUPIXENT, OPSUMIT, GLASSIA, WAKIX, TAVNEOS, TRELEGY ELLIPTA, NUCALA, Sunosi.
Industry payments across AZ — which companies pay providers there.
